Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.
NVS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novartis Ag. To summarize, we found that Novartis Ag ranked in the 38th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for NVS, they are:
The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 24.62% of free cash flow generating stocks in the Healthcare sector.
NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 35.34% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVS, try HRC, MDT, BDX, USPH, and LCI.
Ending almost a decade of litigation, Novartis (NVS) has agreed to pay $678M to resolve a whistleblower case accusing the drugmaker of paying kickbacks to thousands of doctors who prescribed its medicines.As part of the settlement, Novartis will change how the company markets its drugs to doctors as part of...
DUBLIN--(BUSINESS WIRE)--The "Europe Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country" report has been added to ResearchAndMarkets.com's offering. The European antibiotics market is expected to reach US$ 15,569.8 million by 2027 from US$ 12,457.7 million in 2019. The market is estimated to grow with a CAGR of 3.1% from 2020 to 2027. The antibiotics market is growing primarily due to prevalence of infectious diseases and inc
Novartis AG (NYSE: NVS ) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized. What Happened The agreement was made with the U.S. Attorney’s Office for the Southern District of New York, the New York State Attorney General, and the whistleblower Oswald Bilotta. The Government complaint had alleged that between 2002 and 2011, Novartis hosted “tens of thousands” of speaker programs but used these opportunities to bribe doctors. The United States Department of Justice alleged that Novartis violated that federal False Claims Act and Anti-Kickback Statute by providing doctors with cash payments and other inducements, … Full story available on Benzinga.com